$13.41
Live
0.67%
Downside
Day's Volatility :2.45%
Upside
1.79%
29.16%
Downside
52 Weeks Volatility :50.24%
Upside
29.75%
Period | Avadel Pharmaceuticals-adr | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.64% | 3.6% | 0.0% |
6 Months | -21.59% | 10.2% | 0.0% |
1 Year | 29.07% | 19.6% | 0.0% |
3 Years | 65.02% | 16.8% | -23.0% |
Market Capitalization | 1.4B |
Book Value | $0.73 |
Earnings Per Share (EPS) | -1.09 |
PEG Ratio | 0.07 |
Wall Street Target Price | 24.6 |
Profit Margin | -111.64% |
Operating Margin TTM | -30.7% |
Return On Assets TTM | -34.45% |
Return On Equity TTM | -99.52% |
Revenue TTM | 95.1M |
Revenue Per Share TTM | 1.04 |
Quarterly Revenue Growth YOY | 2674.2999999999997% |
Gross Profit TTM | 16.6M |
EBITDA | -97.2M |
Diluted Eps TTM | -1.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.46 |
EPS Estimate Next Year | 0.68 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.07 |
What analysts predicted
Upside of 83.45%
Sell
Neutral
Buy
Avadel Pharmaceuticals-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Avadel Pharmaceuticals-adr | 5.4% | -21.59% | 29.07% | 65.02% | 93.51% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals-adr | NA | NA | 0.07 | -0.46 | -1.0 | -0.34 | NA | 0.73 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Avadel Pharmaceuticals-adr | Buy | $1.4B | 93.51% | NA | -111.64% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Avadel Pharmaceuticals-adr
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 11.7%
HHG PLC
Polar Capital Holdings PLC
Gendell Jeffrey L
BlackRock Inc
Vanguard Group Inc
BRAIDWELL LP
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Organization | Avadel Pharmaceuticals-adr |
Employees | 154 |
CEO | Mr. Gregory J. Divis Jr. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$13.41
-1.14%
Invesco Bulletshares 2025 Hi
$13.41
-1.14%
Schwab International Dividend Equity Etf
$13.41
-1.14%
Blockchain Coinvestors Acquisition Corp.
$13.41
-1.14%
Allgiant Travel Company
$13.41
-1.14%
Rogers Corp
$13.41
-1.14%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$13.41
-1.14%
Iheartmedia
$13.41
-1.14%
Lightpath Technologies Inc
$13.41
-1.14%